Table 1.
Demographic, clinical and radiotracer characteristics for HC and clinical groups imaged before and 24 hours after receiving ketamine
| HC (n=9) | Clinical group (n=12) | |||
|---|---|---|---|---|
| Age (yrs) | 35.11 (12.68) | 39.91 (11.23) | ||
| Sex (m:f) | 6:3 | 8:4 | ||
| Diagnosis | HC | 3 MDD, 4 PTSD, 5 MDD/PTSD | ||
| No. smokers | 2 | 5 | ||
| Age at onset (yrs) | -- | 22.4 (16.6) | ||
| Antidepressant use (n) a | -- | 3 | ||
| Ketamine administered (ml) | 19.23 (2.24) | 21.56 (3.69) | ||
| Baseline | 24hr post-ketamine | Baseline | 24hr post-ketamine | |
| HAMD-17 | 0.88 (0.93) | 0.78 (1.6) | 14.08 (4.42) | 5.92 (4.50) * |
| MADRS | 0.67 (0.87) | 0.78 (1.71) | 18.25 (8.00) | 6.67 (5.07) * |
| BDI | 0.78 (1.30) | 0.89 (1.36) | 21.92 (7.94) | 13.75 (9.40) * |
| PCL-5b | 38.39 (20.33) | 32.71 (17.29) | ||
| PCL-Sc | 30.50 (7.78) | 21.50 (6.36) * | ||
| Injected dose (MBq) | 661.60 (69.83) | 628.75 (89.00) | 490.50 (159.44) | 533.76 (184.64) |
| Injected mass (ng/kg) | 21.83 (9.78) | 16.75 (9.40) * | 14.10 (11.50) | 13.39 (10.42) |
| Free fraction (fp) | 0.28 (0.03) | 0.28 (0.03) | 0.27 (0.02) | 0.28 (0.02) |
| Parent fraction 30mins (%) | 27.35 (5.98) | 26.09 (7.49) | 25.95 (8.19) | 24.33 (6.16) |
| Parent fraction 60mins (%) | 24.19 (3.36) | 24.17 (6.42) | 22.21 (4.95) | 21.39 (4.71) |
| Clearance rate (L/h) | 69.54 (11.00) | 76.82 (16.71) | 81.14 (9.73) | 85.47 (19.74) |
*
significantly different from baseline at p<0.05, as determined by paired-samples t-tests
HAMD-17: Hamilton depression rating scale (17-item); MADRS: Montgomery-Asberg depression rating scale; BDI: Beck depression inventory
a
n=1 subject was taking paxil, n=2 subjects were taking wellbutrin
b
n=6 individuals with PTSD were administered the PCL-5 (DSM-5 version)
c
n=2 individuals with PTSD were administered the PCL-S (DSM-IV version).